Open-label treatment for patients completing study B7A-MC-MBCM

Trial Profile

Open-label treatment for patients completing study B7A-MC-MBCM

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications Diabetic retinopathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Chromaderm; Eli Lilly
  • Most Recent Events

    • 11 Sep 2008 Actual patient number, actual end date added from ClinicalTrials.gov.
    • 11 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top